You are here: Industry Insights > Kesimpta

News List

Tecentriq, Kesimpta lead latest SMC decisions pharmatimes
July 14, 2021
The Scottish Medicines Consortium (SMC) has accepted three new medicines for use by NHS Scotland and rejected one in its July 2021 decisions.
The Scottish Medicines Consortium recommends Novartis’ Kesimpta (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS) firstwordpharma
July 14, 2021
Novartis today announced that eligible patients in Scotland will soon have access to Kesimpta® (ofatumumab), the first self-administered, targeted B-cell therapy for patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined b
Novartis reveals long-term results for MS therapy Kesimpta pharmatimes
June 24, 2021
Novartis has revealed new long-term data for its B-cell targeting therapy Kesimpta, showing that mean immunoglobulin G (IgG) and immunoglobulin M (IgM) were preserved in adults with relapsing multiple sclerosis (MS) receiving the therapy over 3.5 years.
Novartis’ MS therapy Kesimpta wins NICE backing pharmatimes
April 22, 2021
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
Novartis bags EU, UK licences for MS therapy Kesimpta pharmatimes
April 09, 2021
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
EC approves Novartis’s Kesimpta for relapsing multiple sclerosis pharmaceutical-technology
April 01, 2021
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.
EMA committee recommends 13 medicines for approval in January meeting europeanpharmaceuticalreview
February 02, 2021
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
Kesimpta and Vazkepa among latest CHMP recommendations pharmatimes
February 01, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval in its latest meeting.
US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment expresspharma
August 24, 2020
Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL).